![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Poniard Announces Results of Phase 3 Picoplatin Trial
Poniard Announces Results of Phase 3 Picoplatin Trial
May 10, 2010
Poniard Pharmaceuticals, a biopharmaceutical company focused on innovative oncology therapies, Monday announced that data from the Phase 3 trial evaluating the efficacy and safety of picoplatin as a second-line treatment in small cell lung cancer has been accepted for an oral presentation during the American Society of Clinical Oncology 2010 Annual Meeting.
MarketWatch
MarketWatch
Upcoming Events
-
21Oct